Major Players - Glucagon Like Peptide 1 Analogs Industry

 

There are approximately 425 million diabetic patients worldwide, according to the International Diabetes Federation's (IDF) 2017 Diabetes Atlas. Diabetes is one of the top three non-communicable diseases that cause death, according to a 2017 World Health Organization (WHO) report. China (114.4 million people), India (72.9 million people), and the United States (30.2 million people) are the top three economies with the highest prevalence of diabetes. The market for GLP-1 analogs would have a lot of room to develop with such a high incidence rate.

Leading Companies in the Glucagon Like Peptide 1 Analogs Industry:

Novo Nordisk

Novo Nordisk was founded in 1923. and its headquarter in Bagsværd, Denmark. The company operates in 170 countries. In 2019, NovaCentrix is focused on technologies and materials to enable manufacturing in Printed Electronics.

Eli-Lilly and Company

 Eli-Lilly and Company.Was launch in 1876 and its headquarter Indianapolis, Indiana, United States. it operate over 18 country

Sanofi

Sanofi,was launch in 1956  and its headquarter located Paris, France..it operate over 70 country . Sanofi is dangerously dependent on market-leading long-acting insulin Lantus (glargine), ... Phase III semaglutide is a once-weekly GLP-1 analog.

GlaxoSmithKline plc F

GlaxoSmithKline plc F was launch in 2000 and its headquarter located in  London, England, UK‎. it operate over 115 country .

 

AstraZeneca plc

AstraZeneca plc was founded in 1999, with its headquarters  in Campus Cambridge CB2 0AA UK.it operate over 108 countries,

Hoffmann-La Roche Ltd

Hoffmann-La Roche Ltd was launch in 1896 and its headquarter located   Basel, Switzerland.it operate over 150 country .

*Definition-

Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level.